February 10, 2020 Pharmacosmos establishes new specialty pharmaceutical company Pharmacosmos Therapeutics, Inc. in the US

HOLBAEK, DENMARK


Pharmacosmos announces the establishment of the specialty pharmaceutical company Pharmacosmos Therapeutics, Inc. in the US, dedicated to the commercialisation of intravenous iron for the treatment of iron deficiency anaemia (IDA).

Lars Christensen, MD, President and CEO of Pharmacosmos A/S said “I am proud to announce the establishment of Pharmacosmos Therapeutics, Inc. in the US. Built upon the heritage of the global Pharmacosmos Group and its expertise in bringing innovative treatments to patients suffering from iron deficiency anaemia around the world, Pharmacosmos Therapeutics, Inc. will have the benefit of a singular focus with all efforts directed toward covering unmet clinical needs for these patients in the US.

Pharmacosmos Therapeutics, Inc. will expand the ongoing commitment of Pharmacosmos Group to change the way iron deficiency anaemia is treated. Pharmacosmos Therapeutics’ vision is to grow into a complete stand-alone specialty pharmaceutical company that can bring a new treatment option to patients in the fast growing intravenous iron market and, in time, become a leading player in the treatment of iron deficiency anaemia in the United States. said Michael Ryde, CEO of Pharmacosmos Therapeutics, Inc.

Initial members of the leadership team of Pharmacosmos Therapeutics Inc. include

  • Michael Ryde, Chief Executive Officer. Michael has more than 20 years of experience from commercial roles in the pharmaceutical industry, including more than 15 years with Lundbeck, where he was responsible for setting up and leading Lundbeck’s organization in China. During the last 5 years, Michael has been a vice president at Pharmacosmos A/S with responsibility for the commercialisation of intravenous iron products internationally. For the past 3 years, Michael’s work has focused primarily on the go-to-market strategy for intravenous iron in the US.
  • Josh Franklin, Chief Commercial Officer. Josh has more than 20 years of specialty pharmaceutical industry experience, including 15 years in senior commercial executive roles covering corporate development, marketing, and sales. Josh joins Pharmacosmos Therapeutics Inc. from a role as Senior Vice President of marketing and corporate development of Chiesi USA, Inc.
  • Lauren Falcetta, Head of Human Resources. Lauren has more than 20 years of human resources experience in life-sciences industries. Her expertise lies in human resource strategy and design, talent acquisition and development, and linking human resources functions to overall business results. Lauren joins Pharmacosmos Therapeutics Inc. from a role as Director, Human Resources of Ferring Pharmaceuticals.    

Pharmacosmos Therapeutics Inc. is based in Morristown, New Jersey.

For more information, please contact

Robert Guglielmetti, Executive Vice President, Chief Financial Officer
Pharmacosmos A/S
Tel: +45 59 48 59 59

For media inquiries:

Fonnesbech & Estrup
Adam Estrup
Tel: +45 28 74 87 10
e-mail: adam@estrup.dk

About Pharmacosmos Group


Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany and recently also in the US, and through partners, Pharmacosmos markets its products across the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes.

Pharmacosmos